
    
      Enrolled patients will be randomized to either placebo or pioglitazone. Each randomized
      subject will have a skin biopsy and skin irritancy assay performed prior to treatment and at
      the end of 12 weeks of treatment. Noninvasive barrier measurements including transepidermal
      water loss will be recorded at all study visits.
    
  